Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Barry Butler
AddedMar 31, 2024
UpdatedMay 31, 2026
Barry Butler

Barry Butler

Co-Founder, Sirion Therapeutics

Crunchbase

Barry Butler's Career

Sirion Therapeutics
Sirion Therapeutics

Tampa, FL, US

Co-Founder
Betaliq
Betaliq

Tampa, FL, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Barry Butler's Career

Sirion Therapeutics
Sirion Therapeutics
$45M02005Tampa, FL, US
Co-Founder

Leadership at Sirion Therapeutics

Glenn JaffeGlenn JaffeBoard Member
Philippe BoulangeatPhilippe BoulangeatCo-Founder
Liza Page NelsonLiza Page NelsonBoard Member
Richard ParrishRichard ParrishBoard Member
Jason S SlakterJason S SlakterBoard Member
Charles B SlonimCharles B SlonimBoard Member

Similar to Sirion Therapeutics

Sirion HoldingsSirion HoldingsTampa, FL, USMedical Devices, Pharmaceuticalsest. 2006Sirion HoldingsTampa, FL, US · est. 2006

Developing pharmaceuticals and medical devices for eye care, including contract services. Founded in 2006, based in Tampa.

Public · $29.2M30
Eirion TherapeuticsEirion TherapeuticsWoburn, MA, USPharmaceuticalsest. 2016Eirion TherapeuticsWoburn, MA, US · est. 2016

Eirion Therapeutics: Pioneering next-gen prescription dermatology treatments with a rich product pipeline.

Series A · $40M9
Vitreoretinal TechnologiesVitreoretinal TechnologiesIrvine, CA, USDrugs, Pharmaceuticalsest. 1999Vitreoretinal TechnologiesIrvine, CA, US · est. 1999

VitreoRetinal Technologies: A biopharmaceutical firm specializing in ophthalmic drugs and diabetic retinopathy treatment.

Series A · $12M6
SironRX TherapeuticsSironRX TherapeuticsCleveland, OH, USRegenerative Therapiesest. 2010SironRX TherapeuticsCleveland, OH, US · est. 2010

SironRX Therapeutics: Innovating regenerative therapies for wound repair and scar prevention in the US.

Series A · $3.9M6
Betaliq
Betaliq
Seed$6M52018Tampa, FL, US
CEO· C-Suite · Management

Similar to Betaliq

Adtech PharmaAdtech PharmaWarwick, RI, USPharmaceuticalsest. 2021Adtech PharmaWarwick, RI, US · est. 2021

Adtech, a biotech firm, innovates in glaucoma treatment with unique synthetic cannabinoid therapeutics.

Pre-Seed · $6M6
TherOptixTherOptixSan Francisco, CA, USMolecular Treatments, Ocular Therapyest. 2018TherOptixSan Francisco, CA, US · est. 2018

TherOptix: Innovating ocular therapy with effective molecular treatments via a minimally invasive platform.

Series A · $9.5M7
Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
Visus TherapeuticsVisus TherapeuticsSeattle, WA, USEye Dropsest. 2019Visus TherapeuticsSeattle, WA, US · est. 2019

Visus Therapeutics: Pioneering presbyopia-correcting eye drops with 8-hour potential.

Series B · $56M45

People Similar to Barry Butler

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoBrian MartinezBrian MartinezCo-Founder & CEO · Demo LessonKori HandyKori HandyCo-Founder · FounderFoxBill RoyBill RoyFounder · Cavatina CapitalBarry BucklandBarry BucklandBoard Member · Ancora PharmaceuticalsAlan AubreyAlan AubreyCEO · Top Technology VenturesBryan JohnsonBryan JohnsonCo-Founder · OS Fund